The non-proliferative diabetic retinopathy global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Non-Proliferative Diabetic Retinopathy Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.
The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report
Scope Of Non-Proliferative Diabetic Retinopathy Market
The Business Research Company’s reports encompass a wide range of information, including:
Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
Drivers: Examination of the key factors propelling market growth.
Trends: Identification of emerging trends and patterns shaping the market landscape.
Key Segments: Breakdown of the market into its primary segments and their respective performance.
Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
Macro Economic Factors: Assessment of broader economic elements impacting the market.
Non-Proliferative Diabetic Retinopathy Market Overview
Market Drivers –
The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose (blood sugar) due to inadequate production of insulin by the pancreas or the body’s cells becoming resistant to the effects of insulin. Diabetes is caused due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, resulting in vision impairment and potential blindness. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of diabetes associations, approximately 537 million adults (20–79 years old) were living with diabetes in 2021. In contrast, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.
Market Trends –
Major companies operating in the non-proliferative diabetic retinopathy market are developing AI-enabled cameras to improve patient outcomes and advance the field of ophthalmic imaging. AI-enabled cameras in ophthalmic imaging refer to devices equipped with artificial intelligence (AI) algorithms that assist in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, launched Optomed Aurora AEYE, a handheld AI fundus camera designed to detect more than mild diabetic retinopathy instantly. This innovative device combines the portability of a handheld camera with the power of artificial intelligence to provide high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images. This enables quick and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
The non-proliferative diabetic retinopathy market covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Get an inside scoop of the non-proliferative diabetic retinopathy market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
Regional Insights –
North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc. , Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.
Table of Contents
Executive Summary
Non-Proliferative Diabetic Retinopathy Market Report Structure
Non-Proliferative Diabetic Retinopathy Market Trends And Strategies
Non-Proliferative Diabetic Retinopathy Market – Macro Economic Scenario
Non-Proliferative Diabetic Retinopathy Market Size And Growth
…..
Non-Proliferative Diabetic Retinopathy Market Competitor Landscape And Company Profiles
Key Mergers And Acquisitions
Future Outlook and Potential Analysis
Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
